Journal: Cancers

Article Title: The Use of ctDNA for BRAF Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma

doi: 10.3390/cancers14030777

Figure Lengend Snippet: Progression-free survival with BRAF/MEK inhibitors administered based on the ctDNA analysis.

Article Snippet: Tests were performed on 4–5 mL plasma, and ctDNA was isolated immediately after collection. ctDNA was isolated from plasma with QIAamp ® Circulating Nucleic Acid Kit (QIAGEN, Hilden, Germany) and analyzed by quantitative polymerase chain reaction (qPCR) with EntroGen ® ctDNA BRAF Mutation Detection Kit or AmoyDx ® BRAF V600 Mutations Detection Kit (Amoy Diagnostics, Xiamen, China) according to the manufacturer’s protocols.

Techniques:

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Article Title: Liquid Biopsy to Identify Actionable Genomic Alterations

doi: 10.1200/EDBK_199765

Figure Lengend Snippet: Survival Outcome (Progression-Free Survival, Overall Survival, and Survival After Osimertinib Progression) of EGFR T790M Shedders Versus Nonshedders

Article Snippet: 30 The four additional tests reviewed, in addition to the three government-approved tests, were the AmoyDx EGFR 29 mutation detection kit, AmoyDx Super-ARMS EGFR T790M mutation detection kit, Droplet Digital PCR (ddPCR) Dx system (Bio-Rad, Hercules, CA), and PANA Mutyper R EGFR kit (Panagene, Daejeon, Korea).

Techniques:

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Article Title: Liquid Biopsy to Identify Actionable Genomic Alterations

doi: 10.1200/EDBK_199765

Figure Lengend Snippet: Performance Characteristics of OncoBEAM RAS CRC Kit, Idylla ctKRAS, and Idylla ctNRAS-BRAF Mutation Tests

Article Snippet: ​ Despite the widespread use of liquid biopsy in solid malignancy, only five distinct test kits have government approval: Cobas EGFR Mutations Test v2 (Roche Molecular Diagnostics; FDA approval for detection of EGFR del19, EGFR L858R , and EGFR T790M in lung cancer), Therascreen EGFR RGQ Plasma PCR kit (Qiagen Inc; E.U. approval for detection of EGFR del19 and EGFR L858R in lung cancer); AmoyDx Super-ARMS EGFR mutation test (AmoyDx; Chinese Food and Drug Administration approval for detection of EGFR del19 , EGFR 858R, and EGFR T790M in lung cancer); OncoBEAM RAS CRC Kit (Sysmex Inostics; E.U. approval for detection of KRAS and NRAS mutations in colorectal cancer); and Idylla ctKRAS Mutation Test and Idylla ctNRAS-BRAF Mutation Test (Biocartis, Inc.; E.U. approval for detection of KRAS, NRAS , and BRAF mutations in colorectal cancer).

Techniques: Mutagenesis, Digital PCR, Real-time Polymerase Chain Reaction, Sequencing